Latest from University of Chicago Medicine Comprehensive Cancer Center

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.
Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.
Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.
Kiran K. Turaga, MD, associate professor of surgery, vice chief, section of general surgery and surgical oncology, director of the Surgical GI Cancer Program and the Regional Therapeutics Program at The University of Chicago Medicine, discusses whether patients vie for immunotherapy versus surgery as treatment for their melanoma.
Christopher R. Shea, MD, the Eugene J. Van Scott Professor of Medicine, chief of the Section of Dermatology at The University of Chicago Medicine, discusses the dermatological management of melanoma.
Thomas F. Gajewski, MD, PhD, professor of medicine at The University of Chicago Medicine, discusses what targets are currently being explored in patients with melanoma.
Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.
Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.
Publication Bottom Border
Border Publication